middle.news
PYC Therapeutics Shows Durable Vision Gains and Gene Expression in ADOA Trials
8:32am on Tuesday 21st of July, 2026 AEST
•
Biotechnology
Read Story
PYC Therapeutics Shows Durable Vision Gains and Gene Expression in ADOA Trials
8:32am on Tuesday 21st of July, 2026 AEST
Key Points
Non-human primate data shows sustained OPA1 protein increase at 4 months post-dose
ADOA patients exhibit lasting visual acuity improvement and reduced retinal stress
Favourable safety profile with no treatment-related serious adverse events
Clinical protocols to be reviewed for extended dosing intervals beyond 4 months
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE